Cargando…

Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis

BACKGROUND: Relapse is a problem in patients with Crohn’s disease (CD) after medical therapy (including biologics) and after surgery to treat acute inflammation. It is unclear whether the recurrence rate over time is higher after surgical therapy than after continuous drug treatment. AIM: We sought...

Descripción completa

Detalles Bibliográficos
Autores principales: Kneißl, Sarah, Stallhofer, Johannes, Schlattmann, Peter, Stallmach, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560971/
https://www.ncbi.nlm.nih.gov/pubmed/36149447
http://dx.doi.org/10.1007/s00384-022-04254-z
_version_ 1784807865010094080
author Kneißl, Sarah
Stallhofer, Johannes
Schlattmann, Peter
Stallmach, Andreas
author_facet Kneißl, Sarah
Stallhofer, Johannes
Schlattmann, Peter
Stallmach, Andreas
author_sort Kneißl, Sarah
collection PubMed
description BACKGROUND: Relapse is a problem in patients with Crohn’s disease (CD) after medical therapy (including biologics) and after surgery to treat acute inflammation. It is unclear whether the recurrence rate over time is higher after surgical therapy than after continuous drug treatment. AIM: We sought to compare clinical relapse rates and the need for re-interventions (resection or therapeutic endoscopic intervention) in patients with CD. METHODS: A meta-analysis was performed according to PRISMA guidelines. RESULTS: The need for re-intervention with medication or surgery due to surgical or clinical recurrence increased over time. The recurrence rates in patients after ileocecal resection were lower than the rates under biologic therapy. The odds ratio for clinical recurrence under biologics versus after surgical treatment was 2.50 (95% confidence interval [CI] 1.53–4.08, p-value < 0.001). The odds ratio for surgical recurrence under biologics versus after surgery was 3.60 (95% CI 1.06–12.3, p-value 0.041). CONCLUSION: These findings support surgical resection as a treatment option in patients with CD with limited disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-022-04254-z.
format Online
Article
Text
id pubmed-9560971
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95609712022-10-15 Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis Kneißl, Sarah Stallhofer, Johannes Schlattmann, Peter Stallmach, Andreas Int J Colorectal Dis Research BACKGROUND: Relapse is a problem in patients with Crohn’s disease (CD) after medical therapy (including biologics) and after surgery to treat acute inflammation. It is unclear whether the recurrence rate over time is higher after surgical therapy than after continuous drug treatment. AIM: We sought to compare clinical relapse rates and the need for re-interventions (resection or therapeutic endoscopic intervention) in patients with CD. METHODS: A meta-analysis was performed according to PRISMA guidelines. RESULTS: The need for re-intervention with medication or surgery due to surgical or clinical recurrence increased over time. The recurrence rates in patients after ileocecal resection were lower than the rates under biologic therapy. The odds ratio for clinical recurrence under biologics versus after surgical treatment was 2.50 (95% confidence interval [CI] 1.53–4.08, p-value < 0.001). The odds ratio for surgical recurrence under biologics versus after surgery was 3.60 (95% CI 1.06–12.3, p-value 0.041). CONCLUSION: These findings support surgical resection as a treatment option in patients with CD with limited disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-022-04254-z. Springer Berlin Heidelberg 2022-09-23 2022 /pmc/articles/PMC9560971/ /pubmed/36149447 http://dx.doi.org/10.1007/s00384-022-04254-z Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Kneißl, Sarah
Stallhofer, Johannes
Schlattmann, Peter
Stallmach, Andreas
Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title_full Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title_fullStr Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title_full_unstemmed Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title_short Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
title_sort disease recurrence in patients with crohn’s disease after biologic therapy or surgery: a meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560971/
https://www.ncbi.nlm.nih.gov/pubmed/36149447
http://dx.doi.org/10.1007/s00384-022-04254-z
work_keys_str_mv AT kneißlsarah diseaserecurrenceinpatientswithcrohnsdiseaseafterbiologictherapyorsurgeryametaanalysis
AT stallhoferjohannes diseaserecurrenceinpatientswithcrohnsdiseaseafterbiologictherapyorsurgeryametaanalysis
AT schlattmannpeter diseaserecurrenceinpatientswithcrohnsdiseaseafterbiologictherapyorsurgeryametaanalysis
AT stallmachandreas diseaserecurrenceinpatientswithcrohnsdiseaseafterbiologictherapyorsurgeryametaanalysis